Medicare CED Decisions By Local Contractors Would Be Unworkable, Drug Firms Argue
Executive Summary
In comments to the Centers for Medicare and Medicaid Services, drug manufacturers also say CED should continue to be applied only “rarely” for drugs and biologics and should not apply to off-label uses.
You may also be interested in...
CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.